Insulet (NASDAQ:PODD) Stock Rating Lowered by Wall Street Zen

Insulet (NASDAQ:PODD - Get Free Report) was downgraded by analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a report released on Saturday.

A number of other analysts have also commented on the company. Wells Fargo & Company set a $322.00 price objective on Insulet in a research note on Monday, April 28th. The Goldman Sachs Group initiated coverage on Insulet in a report on Friday, May 30th. They issued a "buy" rating and a $380.00 price objective on the stock. Wolfe Research upgraded Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 price objective on the stock in a report on Tuesday, May 13th. Citigroup restated a "buy" rating and set a $380.00 price objective (up previously from $320.00) on shares of Insulet in a research note on Thursday, May 22nd. Finally, Sanford C. Bernstein reaffirmed an "outperform" rating on shares of Insulet in a research note on Friday, May 16th. Four investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $318.41.

Insulet Stock Performance

NASDAQ PODD opened at $304.63 on Friday. The company has a market cap of $21.44 billion, a P/E ratio of 52.61, a P/E/G ratio of 3.62 and a beta of 1.37. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The stock has a 50-day moving average of $287.15 and a two-hundred day moving average of $274.95. Insulet has a 1-year low of $173.00 and a 1-year high of $329.33.

Insulet (NASDAQ:PODD - Get Free Report) last posted its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, topping the consensus estimate of $0.81 by $0.21. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The firm had revenue of $569.00 million during the quarter, compared to analysts' expectations of $543.20 million. During the same quarter in the previous year, the business earned $0.73 earnings per share. The firm's revenue was up 28.8% compared to the same quarter last year. As a group, analysts anticipate that Insulet will post 3.92 EPS for the current year.

Insider Transactions at Insulet

In other news, Director Wayne A.I. Frederick sold 1,825 shares of the company's stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total value of $501,875.00. Following the transaction, the director now owns 3,231 shares in the company, valued at approximately $888,525. This represents a 36.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP John W. Kapples sold 5,278 shares of the business's stock in a transaction that occurred on Wednesday, May 14th. The shares were sold at an average price of $318.47, for a total transaction of $1,680,884.66. Following the transaction, the senior vice president now directly owns 23,180 shares of the company's stock, valued at $7,382,134.60. The trade was a 18.55% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.39% of the stock is currently owned by insiders.

Institutional Trading of Insulet

A number of hedge funds and other institutional investors have recently modified their holdings of PODD. Larson Financial Group LLC grew its stake in Insulet by 426.3% during the first quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier's stock valued at $26,000 after acquiring an additional 81 shares in the last quarter. Zions Bancorporation National Association UT purchased a new position in Insulet in the 1st quarter worth about $26,000. SouthState Corp increased its stake in Insulet by 253.3% in the 1st quarter. SouthState Corp now owns 106 shares of the medical instruments supplier's stock worth $28,000 after buying an additional 76 shares during the period. SBI Securities Co. Ltd. purchased a new position in Insulet in the 4th quarter worth about $36,000. Finally, Itau Unibanco Holding S.A. purchased a new position in Insulet during the 4th quarter valued at about $42,000.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.